Group 1 - The core point of the article is that Baijin Life Sciences (stock code: 1466) announced a financing plan through a general authorization to issue 40,000,000 new shares, raising approximately HKD 19.2 million [1] - The subscription price for the new shares is HKD 0.48 per share, which represents a discount of about 14.29% compared to the closing price of HKD 0.56 on September 29, 2025, and a discount of approximately 10.45% compared to the average closing price of HKD 0.536 over the last five trading days prior to September 26, 2025 [1] - The newly issued shares will account for approximately 5.18% of the existing issued share capital and about 4.92% of the enlarged share capital upon completion [1] Group 2 - The net proceeds from this financing, estimated at around HKD 19.1 million after expenses, will be used to supplement the group's general working capital [1] - The issuance is based on a general authorization granted at the shareholders' meeting and is subject to approval from the Stock Exchange of Hong Kong for the listing and trading of the subscription shares, with completion expected within five business days after the conditions are met [1]